Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 48-week results from a multicentre, randomised, double-blind, phase 2b study.
BACKGROUND Glucagon-GLP-1 dual receptor agonists have shown promise in treating metabolic dysfunction-associated steatohepatitis (MASH). The aim of the IMPACT trial was to assess the effects of one such agent, pemvidutide, in patients with MASH and stage F2 or F3 fibrosis. We previously reported the 24-week primary end...